CJC-1295-DAC | Reference Standard

Long-Acting GHRH Analog for Endocrine & IGF-1 Signaling Research

Category:
Endocrine & Hormonal Signaling • Growth Hormone Axis Research • Peptide Research Compounds

What Researchers Study

CJC-1295 DAC is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) modification. Researchers study this compound for its ability to stimulate endogenous growth hormone (GH) release through GHRH receptor activation while exhibiting prolonged biological presence due to albumin binding.

In research models, CJC-1295 DAC is used to explore sustained modulation of the GH/IGF-1 axis without direct administration of growth hormone itself.

Primary Signal Pathways Studied

Scientific investigation of CJC-1295 DAC focuses on:

• GHRH receptor activation in anterior pituitary somatotrophs

• Endogenous growth hormone secretion dynamics

• Downstream IGF-1 signaling, secondary to GH release

• Albumin-binding peptide pharmacokinetics, via DAC modification

The DAC component enables prolonged receptor stimulation compared to native GHRH or non-DAC analogs, making it useful for extended endocrine signaling studies.

Why This Peptide Is Studied

Native GHRH has a very short biological half-life, limiting its utility in sustained signaling research. CJC-1295 DAC was developed to address this limitation by incorporating an albumin-binding domain, allowing researchers to examine:

• Long-duration GH signaling patterns

• Chronic activation of the GH/IGF-1 axis in preclinical models

• Differences between pulsatile vs sustained endocrine stimulation

This makes CJC-1295 DAC a valuable tool for comparative hormone signaling, endocrine system modeling, and IGF-1 pathway research.

Research Areas of Interest

Endocrine & Hormonal Signaling

CJC-1295 DAC is widely studied in models examining pituitary function, GH secretion patterns, and systemic hormonal coordination.

IGF-1 Axis Research

Because GH release stimulates hepatic IGF-1 production, this compound is frequently used to study downstream growth factor signaling and tissue-level responses.

Peptide Pharmacokinetics

The DAC modification allows investigation into albumin-binding strategies and prolonged peptide stability in circulation.

Selected Scientific References

• Teichman et al., Journal of Clinical Endocrinology & Metabolism — Prolonged GH release following CJC-1295 DAC administration

• Drug Affinity Complex (DAC) technology literature — Albumin-binding peptide stabilization

• American Journal of Physiology — GHRH receptor signaling and GH axis regulation

(References provided for educational context and literature navigation.)

Product Specifications

• Compound Name: CJC-1295 DAC (GHRH analog with Drug Affinity Complex)

• CAS Number: 863288-34-0

• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆

• Amino Acid Sequence:
  Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

• Molecular Weight: ~3647.25 Da

• Purity: ≥98% (HPLC verified)

• Form: Lyophilized powder

• Appearance: White to off-white solid

• Storage: ≤ –20 °C, desiccated, protected from light

Batch Documentation & Traceability

Each vial is shipped with a lot-specific QR code that provides secure access to batch documentation, including:

• Certificate of Analysis (COA)
• Identity verification report (HPLC / MS)
• Lot number, potency, and expiration

Documentation is locked to the specific batch shipped to ensure traceability, version control, and research reproducibility.

QR access is provided with the physical product and is not reused across lots.

Research Use Disclaimer

This product is supplied strictly for laboratory research and in-vitro or preclinical investigation.
Not for human or veterinary use.
Not for diagnostic, therapeutic, or consumptive applications.